Lpath Incorporated

Site 'Main' Navigation:

• Home
• About Lpath
  • Overview
  • Company Summary
  • Pipeline
  • Patent Portfolio
  • Pioneers of the Category
• The Lpath Team
  • Executive Team
  • Board of Directors
  • Advisory Board
• The Science: An Overview
  • Technical Overview
  • Publications/ Presentations/ Grants
• Investor Center
  • Investor Overview
  • Stock Information
  • News Releases
  • Calendar of Events
  • SEC Filings
  • Investor FAQ
  • Request Information
  • Email Alerts
• Legal, Important Notices
• Contact Us

Product Pipeline

Lpath's Product Pipeline Our Proprietary ImmuneY2™ Technology Provides a Valuable Pipeline
	iSONEP™	ASONEP™	Lpathomab™	Nextomabs
Partnership Status		Pfizer Right of First Refusal	Will consider a partnership	Will consider a partnership
Target	Sphingosine 1 Phosphate (S1P)	Sphingosine 1 Phosphate (S1P)	Lysophosphatidic Acid (LPA)	Other bioactive lipids
Lead Indications	Wet AMD, RPE Detachment, Diabetic Retinopathy	Cancer, MS, Inflammation, Colitis	CNS Disorders, Pain, Fibrosis	Inflammation, Cancer, Ocular
Clinical Status	Phase 2	Phase 2	Preclinical	Discovery